|1.||Thase, Michael E: 16 articles (01/2014 - 09/2005)|
|2.||Trivedi, Madhukar H: 13 articles (01/2014 - 10/2004)|
|3.||Ninan, Philip T: 10 articles (01/2014 - 07/2007)|
|4.||Baldwin, David S: 10 articles (11/2013 - 06/2005)|
|5.||Stein, Dan J: 10 articles (11/2013 - 10/2005)|
|6.||Rickels, Karl: 9 articles (07/2014 - 10/2004)|
|7.||Kornstein, Susan G: 9 articles (01/2014 - 09/2005)|
|8.||Pedersen, Ron: 9 articles (04/2013 - 10/2006)|
|9.||Musgnung, Jeff: 9 articles (12/2012 - 01/2006)|
|10.||Loprinzi, Charles L: 9 articles (12/2010 - 11/2002)|
|1.||Major Depressive Disorder (Major Depressive Disorders)
09/01/2010 - "The data from this study indicate that venlafaxine XR is an efficient and safe therapeutic option for patients with major depressive disorder, with the additional effect of reducing associated painful physical symptoms."
04/01/2008 - "The present study indicates that maintenance treatment for 2 years with venlafaxine is cost-effective in patients with recurrent major depressive disorder."
07/01/2002 - "Venlafaxine IR/venlafaxine XR may be effective in outpatients with major depressive disorder who do not respond or have an unsustained response to SSRIs. "
06/21/2000 - "Venlafaxine extended-release (XR) capsules have been shown to be effective in short-term treatment of patients with GAD without major depressive disorder (MDD), but long-term data are needed to establish whether this agent confers persistent benefits. "
06/01/1996 - "The results from this analysis indicate that long-term treatment with venlafaxine in patients with major depressive disorder is effective in maintaining the initial response compared with placebo and suggest that venlafaxine will be effective in the prevention of relapse."
|2.||Anxiety Disorders (Anxiety Disorder)
10/01/2005 - "Venlafaxine extended-release (ER) has proven efficacy in the treatment of anxiety symptoms in major depression, generalised anxiety disorder and social anxiety disorder. "
01/01/2004 - "Venlafaxine is an alternative option, beneficial in depression, post-traumatic stress and generalised anxiety disorders. "
01/01/2005 - "Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial."
01/01/2004 - "Patients with generalized anxiety disorder treated with venlafaxine XR showed similar absolute rates of response on somatic and psychic symptoms, but relative to patients treated with placebo, more improvement in psychic than somatic symptoms."
11/15/2007 - "Venlafaxine ER is an effective and reasonably well-tolerated treatment for generalized social anxiety disorder in children and adolescents. "
03/01/2002 - "Venlafaxine (SNaRI), the most investigated of these new drugs, was shown to be effective in the treatment of different kinds of pain, with side-effects profile significantly better than TCAs. "
01/01/2015 - "In the largest study by Rowbotham, 2004, 56% of participants receiving venlafaxine 150 to 225 mg achieved at least a 50% reduction in pain intensity versus 34% of participants in the placebo group and the number needed to treat for an additional beneficial outcome was 4.5. "
07/01/2010 - "Results of Short-Form 36 (SF-36) indicated that patients who received venlafaxine treatment had a significantly greater improvement in body pain and emotional role compared with those who received placebo treatment (P=0.002 and P=0.002, respectively). "
07/01/2009 - "Venlafaxine significantly reduced pain intensity on the BPI and marginally improved self-reported function. "
04/01/2008 - "Venlafaxine proved to be beneficial in the treatment of both depressive symptoms and chronic pain. "
|4.||Depressive Disorder (Melancholia)
04/01/2006 - "Venlafaxine ER was shown to be an effective and safe drug for the treatment of very elderly primary care patients with depressive syndrome and associated anxiety symptoms."
05/01/2009 - "The results achieved show that treatment with venlafaxine extended release significantly improved the clinical condition of climacteric patients with anxiety or depressive disorder. "
01/01/1997 - "Venlafaxine was effective in outpatients and hospitalized patients with major depression and in those with melancholia, agitated or retarded symptoms, and refractory or treatment-resistant depression. "
01/01/1997 - "Venlafaxine is effective in a broad spectrum of patients, including outpatients and inpatients, those with and without melancholia, patients with symptoms of anxiety or agitation or retardation and patients with first time or recurrent episodes of major depression. "
11/01/2014 - "The aim of this study was to assess whether the combination of low frequency repetitive transcranial magnetic stimulation (rTMS) and venlafaxine (150-225 mg/day) is effective and safe for treatment-resistant unipolar depression (TRD). "
01/01/2007 - "Venlafaxine resulted in modest decreases in hot flashes, but only hot flash interference improved differentially at the higher dose. "
05/01/2003 - "Previous studies have defined that venlafaxine, an anti-depressant, is an effective treatment for such hot flashes. "
11/10/2013 - "In androgen-deprived men, neither venlafaxine nor soy proved effective in reducing hot flashes. "
11/01/2003 - "Venlafaxine is an effective nonhormonal alternative for relief from uncontrolled hot flashes."
01/01/2002 - "The data from this study provides evidence that venlafaxine has intermediate term efficacy and good tolerability as a treatment for hot flashes. "
|1.||Serotonin (5 Hydroxytryptamine)
|2.||Antidepressive Agents (Antidepressants)
|8.||Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors)
|1.||Musculoskeletal Manipulations (Manipulative Therapy)
|2.||Drug Therapy (Chemotherapy)
|4.||Home Nursing (Nursing, Home)